ResearchMoz added Latest Research Report titled " rhEPO Market in China 2016-2020 " to it's Large Report database.
About the Recombinant Human Erythropoietin (rhEPO) Market in China
Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein responsible for producing erythrocytes in the body. In the fetal stage, this protein is produced in the liver; it is secreted by the kidneys in adulthood. During anemic conditions, the body produces an excess of EPO, maintaining the normal levels of red blood cells (RBC). When the endogenous production of EPO is disturbed because of diseases or the use of medications, the normal RBC levels can be maintained by an external supply of EPO-stimulating agents (ESAs). These agents are similar to the natural EPO in structure and function and are administered as injections. They can be produced by recombinant DNA technology and are used to treat anemia due to kidney diseases, cancer, HIV, injuries, or neural diseases.
Technavios analysts forecast the recombinant human erythropoietin (rhEPO) market in China to grow at a CAGR of 16.89% during the period 2016-2020.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=741714
Covered in this report
The report covers the present scenario and the growth prospects of the recombinant human erythropoietin (rhEPO) market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and biosimilars used for the treatment of anemia due to renal diseases, cancer chemotherapy, antiretroviral therapy, and wounds and neural diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
The market is divided into the following segments based on application of rhEPO:
End-stage renal disease (ESRD)
Cancer
Human immunodeficiency virus (HIV)
Wounds and neural disease
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Erythropoietin: An overview
Clinical uses of EPO
Abusive uses of EPO
Risks of EPO use
PART 06: Global erythropoietin market
PART 07: China: Country snapshot
Social and economic conditions
Healthcare reforms
Healthcare infrastructure
PART 08: Opportunities for pharmaceutical vendors in China
Major pharmaceutical vendors in China
Opportunities for global and local vendors
PART 09: Biopharmaceutical market in China
Biosimilar market in China
Market size and forecast
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
About the Recombinant Human Erythropoietin (rhEPO) Market in China
Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein responsible for producing erythrocytes in the body. In the fetal stage, this protein is produced in the liver; it is secreted by the kidneys in adulthood. During anemic conditions, the body produces an excess of EPO, maintaining the normal levels of red blood cells (RBC). When the endogenous production of EPO is disturbed because of diseases or the use of medications, the normal RBC levels can be maintained by an external supply of EPO-stimulating agents (ESAs). These agents are similar to the natural EPO in structure and function and are administered as injections. They can be produced by recombinant DNA technology and are used to treat anemia due to kidney diseases, cancer, HIV, injuries, or neural diseases.
Technavios analysts forecast the recombinant human erythropoietin (rhEPO) market in China to grow at a CAGR of 16.89% during the period 2016-2020.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=741714
Covered in this report
The report covers the present scenario and the growth prospects of the recombinant human erythropoietin (rhEPO) market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and biosimilars used for the treatment of anemia due to renal diseases, cancer chemotherapy, antiretroviral therapy, and wounds and neural diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
The market is divided into the following segments based on application of rhEPO:
End-stage renal disease (ESRD)
Cancer
Human immunodeficiency virus (HIV)
Wounds and neural disease
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Erythropoietin: An overview
Clinical uses of EPO
Abusive uses of EPO
Risks of EPO use
PART 06: Global erythropoietin market
PART 07: China: Country snapshot
Social and economic conditions
Healthcare reforms
Healthcare infrastructure
PART 08: Opportunities for pharmaceutical vendors in China
Major pharmaceutical vendors in China
Opportunities for global and local vendors
PART 09: Biopharmaceutical market in China
Biosimilar market in China
Market size and forecast
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
No comments:
Post a Comment